Pfizer manipulated Neurontin studies, experts allege in fraud case
This article was originally published in Scrip
Executive Summary
Plaintiffs seeking class-action status in US multi-district litigation against Pfizerhave submitted newly filed documents allegedly showing that some of the company's top marketers tried to alter the conclusions of studies or suppress negative information from studies that found no beneficial effect from Neurontin (gabapentin) for various off-label conditions. The case relates to a broad effort by Neurontin users and third-party payers to sue the company for alleged consumer fraud.